Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension

References

• Health, United States, 2012: with special features on emergency care. 2013. Available at: http://www.cdc.gov/nchs/data/hus/hus12.pdf#063 [Last accessed 1 Apr 2013]
   Google Scholar
• Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 2010;303:2043-50
   PubMed Web of Science ®Google Scholar
• Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011;124:1046-58
   PubMed Web of Science ®Google Scholar
• Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006;19:1190-6
   PubMed Web of Science ®Google Scholar
• Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009;120:1598-605
   PubMed Web of Science ®Google Scholar
• Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Medical Care 2005;43:521-30
   PubMed Web of Science ®Google Scholar
• Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012;125:882-7 e1
   PubMed Web of Science ®Google Scholar
• Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens 2009;11:376-82
   PubMed Web of Science ®Google Scholar
• Elliott WJ, Meyer PM. One-year discontinuation rates of antihypertensive drugs in clinical practice: a network meta-analysis [abstract]. J Clin Hypertens (Greenwich) 2007;9(Suppl A):A210
   Google Scholar
• Elliott WJ, Meyer PM, Basu S. One-year persistence with initial antihypertensive drug therapy: a comparison of network and Bayesian meta-analyses [abstract]. J Clin Hypertens (Greenwich) 2008;10(Suppl A5):A113-14
   Google Scholar
• , Centers for Disease CPrevention. Vital signs: prevalence, treatment, and control of hypertension – United States, 1999–2002 and 2005–2008. Morbidity Mortality Weekly Rep 2011;60:103-8
   PubMedGoogle Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
   PubMed Web of Science ®Google Scholar
• Briesacher BA, Andrade SE, Fouayzi H, et al. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008;28:437-43
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Samuelson TM, Ramakrishnan K, et al. Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis. Curr Med Res Opin 2012;28:591-9
   PubMed Web of Science ®Google Scholar
• Messerli FH, Bangalore S. Half a century of hydrochlorothiazide: facts, fads, fiction, and follies. Am J Med 2011;124:896-9
   PubMed Web of Science ®Google Scholar
• Chen JM, Heran BS, Wright JM. Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension. Cochrane Database Syst Rev 2009(4):CD007187
   Google Scholar
• Neutel JM, Smith DH, Gradman AH. Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I–II hypertension. J Human Hypertens 2010;24:64-73
   PubMed Web of Science ®Google Scholar
• Reilly RF, Peixoto AJ, Desir GV. The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis. Clin J Am Soc Nephrol 2010;5:1893-903
   PubMed Web of Science ®Google Scholar
• Truven Health Analytics MarketScan® Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits Research Databases. Ann Arbor, MI
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Steiner JF, Koepsell TD, Fihn SD, et al. A general method of compliance assessment using centralized pharmacy records. Description and validation. Medical Care 1988;26:814-23
   PubMed Web of Science ®Google Scholar
• Halpern MT, Khan ZM, Schmier JK, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006;47:1039-48
   PubMed Web of Science ®Google Scholar
• Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs 2008;8:35-44
   PubMed Web of Science ®Google Scholar
• Weiss RJ, Saunders E, Greathouse M. Efficacy and tolerability of nebivolol in stage I–II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials. Clin Therapeut 2011;33:1150-61
   PubMed Web of Science ®Google Scholar
• Ambrosioni E, Borghi C. Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective beta-blockers in the treatment of hypertension: a meta-analysis. High Blood Pres Cardiovasc Prev 2005;12:27-35
   Google Scholar
• Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 2003;7:1-94
   PubMedGoogle Scholar